ZYVERSA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.40%.
- ZYVERSA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 1 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 11 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|---|---|
| 2025-12-31 | -0.40% 10-K · filed 2026-03-31 | ||
| 2023-12-31 | 0.00% 10-K · filed 2024-03-25 | ||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-25 | ||
| 2022-12-12 | 0.00% 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |